What Ernexa Therapeutics does

Ernexa Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf cell therapies based on a proprietary induced mesenchymal stem cell (iMSC) platform. The company's core technology engineers induced pluripotent stem cells (iPSCs) — reprogrammed from adult cells — and differentiates them into synthetic iMSCs that exploit the natural tumor- and inflammation-homing behavior of mesenchymal stem cells to deliver therapeutic cytokine payloads directly at disease sites. Ernexa's lead candidate, ERNA-101, is an allogeneic iMSC therapy secreting an IL-7/IL-15 cytokine payload designed to remodel the immunosuppressive tumor microenvironment and convert immunologically 'cold' tumors to 'hot,' with an initial indication in platinum-resistant ovarian cancer. A second candidate, ERNA-201, applies the same iMSC architecture to deliver IL-10 to inflamed tissues for autoimmune disease, initially rheumatoid arthritis. Both candidates are supported by an extensively patented foundational mRNA cell engineering technology platform and additional pending claims covering IL-7/IL-15 expression constructs (P2A and FUS configurations) and beta-2-microglobulin knockout (B2M-KO) iMSC lines intended to reduce allogeneic immune clearance.

Ernexa is advancing ERNA-101 toward an IND submission targeted for Q3 2026 and a first-in-human Phase 1 study in Q4 2026, with manufacturing process development transitioned to GMP manufacturing via a partnership with Cellipont Bioservices. The company plans to pursue sub-licensing and Phase 2 partnership opportunities in the second half of 2027, framing its long-term revenue model around licensing/royalty arrangements and, eventually, pharmaceutical product sales following regulatory approval. The company is publicly traded on Nasdaq under ticker ERNA, headquartered in Cambridge, Massachusetts, and operates with a small team of approximately 1–10 employees supplemented by an extensive scientific and medical advisory board whose members include domain experts from MD Anderson Cancer Center and other leading institutions.

Financially, Ernexa is pre-revenue and pre-commercial. It has funded operations through a series of equity financings, most recently a $10.5 million public offering in February 2026 (21 million shares at $0.50 with warrants at $0.68), supplementing a prior $7.25 million private placement (April 2025) and a $5 million PIPE investment. The company completed a 1-for-25 reverse stock split effective May 4, 2026 to maintain Nasdaq listing compliance following a 90% prior-year decline in share price and a delisting notice triggered by the stock falling below the $1.00 minimum bid price. Management has also reduced general and administrative expenses by approximately 61% year-over-year and reported a 44% decrease in operational loss, extending stated cash runway to 12–18 months as it focuses resources on advancing ERNA-101 toward the clinic. The company has additionally been selected for JETRO's Japan Entry Acceleration Program (JEAP), positioning it for potential entry into the Japanese regenerative medicine market.

Name

Ernexa Therapeutics

Legal name

Ernexa Therapeutics Inc.

Website

https://ernexatx.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1–10 employees

Short description

Ernexa Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company developing allogeneic iPSC-derived mesenchymal stem cell (iMSC) therapies that deliver cytokine payloads to disease sites, with lead candidate ERNA-101 targeting platinum-resistant ovarian cancer and ERNA-201 targeting autoimmune disease.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Allogeneic cell therapy
• Cancer immunotherapy
• Cytokine-based therapies
• IPSC-derived therapeutics
• Autoimmune disease treatment

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Cell Therapy Product Revenue: As a pre-commercial biotechnology company, Ernexa does not yet have product revenue. The company is developing cell therapy candidates ERNA-101 (ovarian cancer) and ERNA-201 (autoimmune disease) with plans to commercialize upon regulatory approval. Future revenue is expected from pharmaceutical product sales following clinical development and regulatory clearance.
2. Strategic Partnerships and Licensing: The company plans to pursue sub-licensing and partnering opportunities for its technology platform and pipeline candidates. The pipeline offers multiple clinical applications with future sub-licensing and partnering opportunities, particularly for Phase 2 development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Ernexa Therapeutics develops engineered allogeneic induced mesenchymal stem cells (iMSCs) derived from induced pluripotent stem cells (iPSCs) for use as off-the-shelf cell therapies. Its lead candidates, ERNA-101 (delivering IL-7/IL-15 to ovarian cancer tumors) and ERNA-201 (delivering IL-10 to inflamed tissues for autoimmune disease), are designed to home to disease sites and deliver targeted cytokine payloads. The company is pre-commercial and advancing toward IND submission for ERNA-101 in Q3 2026.

Product overview

Ernexa Therapeutics is developing a portfolio of off-the-shelf, synthetic cell therapies based on its proprietary iMSC (induced mesenchymal stem cell) platform. The platform engineers iPSCs into iMSCs that home to disease sites and deliver targeted cytokine payloads. The lead product candidates are ERNA-101 (for oncology, targeting ovarian cancer) and ERNA-201 (for autoimmune diseases, targeting rheumatoid arthritis), both leveraging the same core iMSC technology with different cytokine payloads and therapeutic purposes.

Differentiator

Problem solved

Functional benefit

Brands

• ERNA-101: Lead cell therapy candidate targeting ovarian cancer, designed to activate and enhance the immune system's response to recognize and attack cancer cells using engineered iMSCs secreting IL-7/IL-15 cytokines.
• ERNA-201
• iMSC Platform

Products and services

• ERNA-101
• ERNA-201
• iMSC Platform

Quantifiable outcome

• 100% long-term survival and complete tumor elimination in syngeneic ovarian cancer mouse models when ERNA-101 combined with PD-1 blockade
• +3 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered strategic and core.

• Japan External Trade Organization (JETRO)strategicStrategic or Co-development Partner · 27 January 2026Ernexa was selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative. As a participant, Ernexa receives expert-led mentoring and market-entry guidance focused on Japan's regulatory, clinical and commercial landscape, plus engagement opportunities with Japanese R&D organizations, CDMOs and CROs.
• Cellipont BioservicescoreTechnology or Integration · 30 October 2025Cellipont Bioservices partnered with Ernexa Therapeutics to support the development and manufacturing of ERNA-101 cell therapy for ovarian cancer into clinical trials. The collaboration focuses on manufacturing process development and technology transfer activities supporting clinical trial preparations. Cellipont is providing GMP manufacturing capabilities as Ernexa advances toward becoming a clinical-stage biotechnology company.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerErnexa's approach builds on the foundational work of world-renowned expert Michael Andreeff, M.D., Ph.D. from The University of Texas MD Anderson Cancer Center. Dr. Andreeff's studies showed that engineered mesenchymal stem cells can successfully home to tumor sites, deliver immunostimulatory molecules, and reduce tumor burden in preclinical ovarian cancer models. This scientific collaboration underlies the company's core technology platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell candidates for cancer. Most directly comparable to Ernexa given shared iPSC engineering foundation and allogeneic, off-the-shelf modality.
• Century Therapeutics: Century Therapeutics develops allogeneic iPSC-derived NK and T-cell therapies with engineered features to evade immune rejection. Closely comparable to Ernexa's iPSC platform, allogeneic approach, and use of gene editing (e.g., B2M knockouts) to enhance persistence.
• Mesoblast: Mesoblast develops allogeneic mesenchymal stem cell (MSC) therapies for inflammatory and immune-mediated diseases, including graft-vs-host disease and heart failure. Direct MSC therapy peer even though Ernexa's iMSCs are iPSC-derived rather than bone-marrow-derived.
• Cynata Therapeutics: Cynata is developing iPSC-derived MSC therapies for inflammatory and autoimmune indications, including graft-vs-host disease and osteoarthritis. Highly comparable to Ernexa given shared iPSC-to-MSC manufacturing platform and target indications in inflammation/autoimmunity.
• Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapy products for inflammatory and ischemic conditions. Comparable as a non-iPSC off-the-shelf cell therapy peer targeting similar inflammatory/autoimmune use cases as ERNA-201.
• Nkarta Therapeutics: Nkarta develops allogeneic NK cell therapies engineered with cytokine payloads (including IL-15) for oncology. Comparable to Ernexa given shared strategy of using engineered allogeneic cells to deliver immunostimulatory cytokines to tumors.
• Celularity: Celularity develops placenta-derived allogeneic cell therapies including MSC and NK candidates for cancer and autoimmune indications. Comparable to Ernexa in off-the-shelf cell therapy modality and oncology/autoimmune target indications.

Emerging players

• Shoreline Biosciences: Shoreline Biosciences is a private iPSC-derived NK and macrophage cell therapy developer with partnerships with Kite and BeiGene. Emerging player comparable on iPSC platform and engineered immune cell approach, though focused on NK/macrophage rather than MSC.
• Caribou Biosciences: Caribou develops allogeneic CAR-NK cell therapies using CRISPR gene editing to enhance persistence and efficacy. Comparable to Ernexa as a small clinical-stage cell therapy peer using engineered allogeneic cells, though focused on CAR-NK rather than cytokine-secreting MSCs.

Broad incumbents

• Gilead Sciences (Kite Pharma): Gilead/Kite is the leading commercial cell therapy company with approved autologous CAR-T products (Yescarta, Tecartus). Broad incumbent in oncology cell therapy and a likely strategic acquirer or partner for emerging players like Ernexa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ernexa-therapeutics/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ernexa Therapeutics